000 | 02820nam a22004815i 4500 | ||
---|---|---|---|
001 | 978-3-662-44596-9 | ||
003 | DE-He213 | ||
005 | 20160405110621.0 | ||
007 | cr nn 008mamaa | ||
008 | 140906s2014 gw | s |||| 0|eng d | ||
020 |
_a9783662445969 _9978-3-662-44596-9 |
||
024 | 7 |
_a10.1007/978-3-662-44596-9 _2doi |
|
050 | 4 | _aQR355-502 | |
072 | 7 |
_aMMFM _2bicssc |
|
072 | 7 |
_aMED052000 _2bisacsh |
|
082 | 0 | 4 |
_a616.9101 _223 |
245 | 1 | 0 |
_aMicrobicides for Prevention of HIV Infection _h[electronic resource] / _cedited by Jeremy Nuttall. |
264 | 1 |
_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg : _bImprint: Springer, _c2014. |
|
300 |
_aIX, 179 p. 12 illus., 6 illus. in color. _bonline resource. |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
347 |
_atext file _bPDF _2rda |
||
490 | 1 |
_aCurrent Topics in Microbiology and Immunology, _x0070-217X ; _v383 |
|
505 | 0 | _aCandidate Microbicides and Their Mechanisms of Action -- Microbicide Dosage Forms -- Preclinical Safety Evaluation -- Clinical Safety and Pharmacology Trial -- Microbicides for Prevention of HIV Infection: Clinical Efficacy Trials -- Rectal Microbicide Development -- Developing Regulatory Strategy for Microbicides -- Preparing for Microbicide Introduction, Rollout and Sustained Access. | |
520 | _aOne of the most promising new approaches for the prevention of HIV transmission, particularly for developing countries, involves topical, self-administered products known as microbicides. The development of microbicides is a long and complicated process, and this volume provides an overview of all the critical areas, from the selection of appropriate candidate molecules and their formulation, preclinical and clinical testing for safety and efficacy, strategies for product registration and finally, issues associated with product launch, distribution and access. The book will prove valuable to both those working in the field and all others who are interested in learning more about this product class, which has the potential to significantly impact the future of this devastating epidemic. | ||
650 | 0 | _aMedicine. | |
650 | 0 | _aVaccines. | |
650 | 0 | _aPharmaceutical technology. | |
650 | 0 | _aVirology. | |
650 | 1 | 4 | _aBiomedicine. |
650 | 2 | 4 | _aVirology. |
650 | 2 | 4 | _aVaccine. |
650 | 2 | 4 | _aPharmaceutical Sciences/Technology. |
700 | 1 |
_aNuttall, Jeremy. _eeditor. |
|
710 | 2 | _aSpringerLink (Online service) | |
773 | 0 | _tSpringer eBooks | |
776 | 0 | 8 |
_iPrinted edition: _z9783662445952 |
830 | 0 |
_aCurrent Topics in Microbiology and Immunology, _x0070-217X ; _v383 |
|
856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-3-662-44596-9 |
912 | _aZDB-2-SBL | ||
999 |
_c3034 _d3034 |